Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer

NCT05795101 is registered in ClinicalTrials.gov with Filipa Lynce, MD as lead sponsor.

NCT NCT05795101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05795101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer
Lead sponsor
Filipa Lynce, MD
Phase
Phase 2
Overall status
Recruiting
Start date
May 4, 2023
Completion date
December 1, 2032
Enrollment
63 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2 low breast adenocarcinoma, her2-positive breast cancer, inflammatory breast cancer stage iii, invasive breast cancer